Pluristem Therapeutics Inc.,
Keeping people healthier for longer.

It’s no secret that people are living longer, and according to World Health Organization (WHO) by 2050 over 2 billion people will be over 60 years of age. One of the unfortunate side effects of longer life, however, is more people will suffer from medical conditions that result from aging. The costs of the health care systems and the economic burden will inevitably increase .That’s where Pluristem comes in.

 

Pluristem (NASDAQ , TASE: PSTI) is a leading regenerative medicine company developing novel placenta-based cell therapy products (PLX) that treat patients by stimulating their bodies’ own regenerative mechanisms. PLX cell products are off-the-shelf, requiring no tissue matching prior to administration, and can be delivered in any clinical setting through a simple intra-muscular injection. The injected cells release therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders, and radiation damage. 

 

The Company is currently conducting advanced stage clinical trials and nearing commercialization to deliver regenerative treatments. “Our two Phase III studies alone address multi-billion markets and critical unmet medical needs with regenerative treatments that are cost-effective and easy to deliver. Age-related chronic medical conditions will increase healthcare costs and require new and innovative ways to treat complex diseases. Pluristem aims to deliver regenerative medicine that will heal patients around the world, keeping people healthier for longer,” said Pluristem President & CEO Yaky Yanay.

 

Pluristem’s robust clinical pipeline includes two Phase III studies for its PLX-PAD product and two additional studies for its PLX-R18  product.  A pivotal Phase III study in critical limb ischemia treats R5 patients who are unsuitable for revascularization surgery. The Company’s second Phase III study in muscle regeneration following hip fracture surgery addresses a growing need for an aging  population, as there is currently no approved treatment for post-operative muscle regeneration. The Company’s PLX-PAD product was accepted as part of European Union’s accelerated adaptive pathway program,  and the FDA Fast Track Designation.

 

Pluristem has one of the most robust IP portfolios in the cell therapy space with 140 granted and allowed patents, company-owned and operated, GMP-certified manufacturing and research facilities which is scalable and ready for marketing phase. Over $300M have been invested in the company since inception, of them $100M invested as non-dilutive funding such as the Israel innovation authority, the horizon 2020 program, and others. In addition, Pluristem also has strategic relationships with leading international collaborations that include the U.S. National Institutes of Health, Department of Defense, NASA, Duke University, Fukushima Medical University, Hadassah Medical Center, CHA Biotech, Thermo Fisher Scientific, and Charite’ among others. 

 

For more information about how Pluristem can help people live healthier for longer visit www.pluristem.com

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.

© 2020 Family Office Research, Consulting & Events All Rights Reserved.